Clinical Trial Update: A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on a dose-escalation study of briquilimab in adults with chronic inducible urticaria that remained symptomatic despite H1 ant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inducible Urticaria

Drugs mentioned

• Briquilimab

Snippet

Sponsor: Jasper Therapeutics, Inc. | Conditions: Chronic Inducible Urticaria | Phase 1, Phase 2 | Status: TERMINATED